Showing results (51-60 of 223) with videos related to

Sort By:
Pageof 23
British Journal of Cancer|September 12, 2025
Acceptance of external control arms by HTA agencies: a review of oncology submissions in France, England, Germany and Norway from 2021 to 2023Matthias Monnereau, Jean-Pierre Delord, Stefan Michiels, et al.
Bulletin Du Cancer|October 17, 2017
[Observational study of outpatient unit duration of stay depending on the route of administration (intravenous vs subcutaneous) for a targeted therapy]Frédéric Despiau, Yann Zagala, Jean-Pierre Delord, et al.
JCI Insight|December 17, 2020
PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cellsCamille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Serum cystatin C is a better marker of topotecan clearance than serum creatinineAntje Hoppe, Sophie Séronie-Vivien, Fabienne Thomas, et al.
BMC Cancer|June 4, 2020
Improving communication between the general practitioner and the oncologist: a key role in coordinating care for patients suffering from cancerVladimir Druel, Laetitia Gimenez, Kim Paricaud, et al.
Melanoma Research|August 28, 2015
Acute skin reaction suggestive of pembrolizumab-induced radiosensitizationVincent Sibaud, Isabelle David, Laurence Lamant, et al.
Cancer Chemotherapy and Pharmacology|March 21, 2003
Population pharmacokinetics of oxaliplatinJean-Pierre Delord, Amine Umlil, Rosine Guimbaud, et al.
Oncology|January 12, 2008
A phase I dose-escalating and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancerJean Pierre Delord, Florence Dalenc, Frédéric Pinguet, et al.
Journal of Ovarian Research|April 18, 2014
Evaluation of the effects of hyaluronic acid-carboxymethyl cellulose barrier on ovarian tumor progressionLaetitia Picaud, Benoît Thibault, Eliane Mery, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i>-Mutant MelanomaJean-Pierre Delord, Caroline Robert, Marta Nyakas, et al.
Pageof 23